Galmed Pharmaceuticals Ltd (GLMD) CFO Josh Blacher says that in clinical studies its product candidate aramchol has displayed significant activity in reducing liver fat concentration. This reduction may be critical in patients suffering from NASH, or nonalcoholic steatohepatitis.
“It’s our belief, based on our research and scientific literature, that the excessive fat is in fact the root cause of the liver’s deterioration,” Blacher says. “As such, we believe that if you can inhibit the production and accumulation of liver fat, you prevent the domino effect of the inflammation. So that’s in fact what we are aiming to do, and that is our mechanism of action: to inhibit the production and retention of liver fat.”
FOR MORE INFORMATION ON THIS INTERVIEW CLICK HERE.
Blacher says the NASH market currently has no improved drugs, yet is estimated to be between 5% and 10% of the adult population.
“It is thought to be one of the largest unmet medical needs in the U.S. right now. The estimates by Wall Street analysts for the market potential are between $10 billion and $70 billion a year, so this is a big one with nothing on the market,” Blacher says.
Fabry Disease, Gaucher Disease, Pompe Disease and Cystinosis: AVROBIO has One Gene Therapy Platform to Treat them All
November 01, 2018
Coronado Biosciences (CNDO) Uses Trichuris Suis Ova to Treat Autoimmune Diseases
May 20, 2013
OncoMed Pharmaceuticals (OMED) Early-Stage Cancer Antibodies Could Raise Stock 50% in October
September 24, 2013
Crohn's Disease Cure Results from this Biotech Top Pick from Dr. Steve Brozak
March 27, 2019
LDK Solar Co., Ltd (ADR) (LDK) Works to Resolve Offshore Liquidity Issues
March 04, 2014
